Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Neramexane Clear all
Completed Phase 3 Interventional

The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

NCT00090116
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Neramexane
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
34
States / cities
Peoria, Arizona • Phoenix, Arizona • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects

NCT00983099
View directory record Official record
Conditions
Healthy
Interventions
Neramexane
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
20 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 4, 2026, 10:28 PM EDT
Terminated Phase 3 Interventional

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

NCT00827008
View directory record Official record
Conditions
Subjective Tinnitus
Interventions
Neramexane mesylate
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
31
States / cities
Tucson, Arizona • Burbank, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

NCT00955799
View directory record Official record
Conditions
Subjective Tinnitus
Interventions
Neramexane mesylate, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
39
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Sep 4, 2026, 10:28 PM EDT